Published in Cytometry A on September 13, 2011
Measurements of treatment response in childhood acute leukemia. Korean J Hematol (2012) 0.84
Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells. Arch Med Res (2015) 0.78
Unraveling Sugar Chain Signatures of the "Seeds" of Tumor Metastasis. J Proteomics Bioinform (2017) 0.75
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
A rare-cell detector for cancer. Proc Natl Acad Sci U S A (2004) 3.95
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
High speed detection of circulating tumor cells. Biosens Bioelectron (2006) 2.29
Laser-scanning cytometry: A new instrumentation with many applications. Exp Cell Res (1999) 1.92
Cellular image analysis and imaging by flow cytometry. Clin Lab Med (2007) 1.92
Multispectral imaging of hematopoietic cells: where flow meets morphology. J Immunol Methods (2008) 1.74
Is there a role for circulating tumor cells in the management of breast cancer? Clin Cancer Res (2008) 1.67
Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia (2004) 1.65
Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry (1999) 1.53
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood (2010) 1.47
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood (2002) 1.28
Immunophenotyping of leukemia. J Immunol Methods (2000) 1.25
Granulocytes and cultured human fibroblasts express common acute lymphoblastic leukemia-associated antigens. Blood (1983) 1.12
Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen. J Exp Med (1983) 1.10
Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat (2011) 1.08
Ultra-rare-event detection performance of a custom scanning cytometer on a model preparation of fetal nRBCs. Cytometry (2000) 1.06
Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol (2009) 1.04
Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol (1997) 0.95
Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol (2002) 0.94
Equivalence of laser scanning cytometric and flow cytometric immunophenotyping of lymphoid lesions in cytologic samples. Am J Clin Pathol (2008) 0.93
Minimal residual disease studies by flow cytometry in acute leukemia. Acta Haematol (2004) 0.91
Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes Chromosomes Cancer (1999) 0.88
Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica (2003) 0.87
CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia. Am J Clin Pathol (2005) 0.86
Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia (1995) 0.84
Practical application of minimal residual disease assessment in childhood acute lymphoblastic leukaemia annotation. Br J Haematol (2001) 0.81
Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome. Leukemia (1998) 0.80
In patients with BCR-ABL-positive ALL in CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT. Ann Hematol (1994) 0.79
Improved detection of rare CALLA-positive cells in peripheral blood using multiparameter flow cytometry. J Immunol Methods (1984) 0.77
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89
Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95
Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther (2009) 6.91
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21
A rare-cell detector for cancer. Proc Natl Acad Sci U S A (2004) 3.95
Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76
Primary B cell immunodeficiencies: comparisons and contrasts. Annu Rev Immunol (2009) 2.97
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood (2005) 2.81
Circulating tumor cells from well-differentiated lung adenocarcinoma retain cytomorphologic features of primary tumor type. Arch Pathol Lab Med (2009) 2.73
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital. Blood (2009) 2.70
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2012) 2.55
Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res (2010) 2.51
Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res (2009) 2.37
High speed detection of circulating tumor cells. Biosens Bioelectron (2006) 2.29
Case study of the morphologic variation of circulating tumor cells. Hum Pathol (2006) 2.28
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia. Blood (2007) 2.19
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia. Blood (2012) 2.14
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest (2007) 2.05
Structure and thermodynamic characterization of the EphB4/Ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure (2006) 1.97
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood (2012) 1.90
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood (2011) 1.88
New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood (2011) 1.78
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood (2002) 1.74
Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol (2011) 1.71
Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling. Blood (2013) 1.70
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood (2011) 1.68
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy (2012) 1.67
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia. J Clin Oncol (2005) 1.53
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol (2011) 1.52
Enthalpy arrays. Proc Natl Acad Sci U S A (2004) 1.52
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood (2010) 1.47
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood (2005) 1.42
Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia. Br J Haematol (2003) 1.41
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2. Blood (2006) 1.41
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome. Blood (2006) 1.40
Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol (2005) 1.35
Development and functional characterization of human bone marrow mesenchymal cells immortalized by enforced expression of telomerase. Br J Haematol (2003) 1.33
Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J Clin Oncol (2014) 1.31
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol (2012) 1.30
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood (2004) 1.30
Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study. J Clin Oncol (2012) 1.29
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia. Blood (2002) 1.28
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy (2012) 1.27
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104. PLoS One (2011) 1.23
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. J Natl Cancer Inst (2011) 1.23
Replicative potential of human natural killer cells. Br J Haematol (2009) 1.19
Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol (2010) 1.19
Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol (2010) 1.16
2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells. Clin Cancer Res (2009) 1.15
Synthetic messenger RNA as a tool for gene therapy. Hum Gene Ther (2006) 1.13
Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15. Br J Haematol (2011) 1.10
Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood (2010) 1.10
Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat (2011) 1.08
Minimal residual disease quantitation in acute myeloid leukemia. Clin Lymphoma Myeloma (2009) 1.07
Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group. J Clin Oncol (2009) 1.06
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica (2012) 1.05
Higher throughput calorimetry: opportunities, approaches and challenges. Curr Opin Struct Biol (2010) 1.04
Enthalpy array analysis of enzymatic and binding reactions. Anal Biochem (2008) 1.03
A chimeric receptor with NKG2D specificity enhances natural killer cell activation and killing of tumor cells. Cancer Res (2013) 1.02
Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol (2007) 1.02
Expansion and activation of natural killer cells for cancer immunotherapy. Korean J Lab Med (2009) 1.02
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients. J Immunother (2015) 1.01
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther (2011) 1.00
A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids (2013) 0.99
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer (2013) 0.98
Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. Haematologica (2006) 0.98
T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res (2013) 0.98
Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse. Cancer (2008) 0.95
Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics (2011) 0.93
Should evaluation for minimal residual disease be routine in acute myeloid leukemia? Curr Opin Hematol (2013) 0.92
Integrated analysis of pharmacologic, clinical and SNP microarray data using Projection Onto the Most Interesting Statistical Evidence with Adaptive Permutation Testing. Int J Data Min Bioinform (2011) 0.91
Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity. J Exp Clin Cancer Res (2010) 0.90
Measurement of enzyme kinetics and inhibitor constants using enthalpy arrays. Anal Biochem (2009) 0.90
Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer (2012) 0.90
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients. Blood (2013) 0.87
Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer (2012) 0.86
Childhood acute lymphoblastic leukemia. Rev Clin Exp Hematol (2002) 0.86
Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol (2010) 0.86
Combination chemotherapy with clofarabine, cyclophosphamide, and etoposide in children with refractory or relapsed haematological malignancies. Br J Haematol (2011) 0.85
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol (2014) 0.84
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer (2014) 0.84
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia. Cancer (2013) 0.82
Detection of minimal residual disease in pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom (2013) 0.82
Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing. Best Pract Res Clin Haematol (2010) 0.82
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics (2013) 0.81
Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer. Int J Cancer (2014) 0.81
Growth requirements and immunophenotype of acute lymphoblastic leukemia progenitors. Blood (2005) 0.81
Rapid mixing of sub-microlitre drops by magnetic micro-stirring. Lab Chip (2011) 0.81
Minimal residual disease monitoring by flow cytometry. Best Pract Res Clin Haematol (2003) 0.80
Characterization of CD34+, CD13+, CD33- cells, a rare subset of immature human hematopoietic cells. Haematologica (2002) 0.80
The immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report. Br J Haematol (2012) 0.78
Natural killer cell reprogramming with chimeric immune receptors. Methods Mol Biol (2013) 0.78